Pliant Therapeutics Shares it 52-Week Low

Pliant Therapeutics stock tumbles amid IPF trial cancellation
The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
Pliant Therapeutics Shares it 52-Week Low After Phase2b Trial Discontinued
Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week low of $1.53 earlier in the session, and is now down 90% n the past 12 months.
Pliant Therapeutics shares rise on better-than-expected Q4 earnings
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel,
Pliant Therapeutucs Shares Halted After Bexotegrast Phase 2b Trial Discontinued
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Hosted on MSN5h
Pliant Therapeutics Reports Q4 2024 Results and Updates
Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
ENDPOINTS NEWS16h
Pli­ant calls it quits on Phase 2b id­io­path­ic pul­monary fi­bro­sis study
Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Fintel on MSN21d
JP Morgan Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Overweight to Neutral. Analyst Price Forecast Suggests 1,212.38% Upside As of ...
Pliant Therapeutics (PLRX) Projected to Post Earnings on Tuesday
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...